Do analysts agree on Tonix Pharmaceuticals (Tonix) stock's price target?
The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts' consensus price target of $2.00, Tonix Pharmaceuticals has a forecasted upside of 740.7% from its current price of $0.24.
Where can I buy shares of TNXP?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is TNXP a buy or sell on Robinhood?
Today TNXP ranks #13176 as sell candidate. Get a Free Stock at Robinhood On Aug 11, 2021 "Alliance Global Partners" gave "$4.00 - $2.00" rating for TNXP. The price target was set to $0.78+10.8%. The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity.
Is TNXP a good stock to buy?
Is Tonix Pharmaceuticals Holding Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: TNXP) stock is to Buy TNXP stock.
Will TNXP be delisted?
The Company's common stock was transferred to the Nasdaq Capital Market effective as of March 3, 2022, and will continue to trade under the symbol “TNXP.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed ...
Does TNXP ever recover?
In total, the company plans to have three programs entering into phase 2 trials by the end of 2021. That means 2022 and 2023 could easily be better for investors than this year. And investors can be confident that Tonix will survive for the near future.
Why is tonix stock dropping?
The company's stock lost nearly one-third of its value after the company announced a financial engineering move that sent investors scrambling for the exits. Tonix announced Monday afternoon that it is effecting a 1-for-32 reverse split of its common stock.
What is the future of TNXP?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) The 1 analysts offering 12-month price forecasts for Tonix Pharmaceuticals Holding Corp have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +740.34% increase from the last price of 1.19.
Is TNXP going to reverse split?
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 17, 2022.
Why did TNXP stock drop in 2018?
Brittany Meiling. After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company's stock Friday morning.
How much cash does tonix pharmaceuticals have?
Tonix Pharmaceuticals Holding cash on hand from 2010 to 2022....Compare TNXP With Other Stocks.Tonix Pharmaceuticals Holding Annual Cash on Hand (Millions of US $)2021$1792020$772019$112018$259 more rows
When did tonix pharmaceuticals go public?
It was listed on the NASDAQ exchange in 2013 under the symbol TNXP. Ernest Mario, a scientist and former CEO of Glaxo Holdings Inc, served on the board of Tonix in the past.
What is a 1 for 32 reverse split?
As a result of the reverse stock split, every thirty-two pre-split shares of common stock outstanding will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common stock from 1,600 million to 50 million shares.
What is the reason for a stock split?
The main reason a company would want to split its stock is to make the share price more affordable to everyday investors and, in turn, boost liquidity.
What does a 1 for 4 reverse stock split mean?
In a 1-for-4 split, a shareholder of four shares will end up with one share. The price of one share will be the sum of all the four shares, enhancing the per-share value. The market capitalization value remains the same as there are no new additions, only a restructuring.
What is Tonix Pharmaceuticals's consensus rating and price target?
According to the issued ratings of 2 analysts in the last year, the consensus rating for Tonix Pharmaceuticals stock is Buy based on the current 2...
Do Wall Street analysts like Tonix Pharmaceuticals more than its competitors?
Analysts like Tonix Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for Tonix Pharmaceuticals is 3...
Do MarketBeat users like Tonix Pharmaceuticals more than its competitors?
MarketBeat users like Tonix Pharmaceuticals stock more than the stock of other Medical companies. 70.15% of MarketBeat users gave Tonix Pharmaceuti...
Does Tonix Pharmaceuticals's stock price have much upside?
According to analysts, Tonix Pharmaceuticals's stock has a predicted upside of 171.97% based on their 12-month price targets.
What analysts cover Tonix Pharmaceuticals?
Tonix Pharmaceuticals has been rated by Noble Financial in the past 90 days.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now. Just click the link above.
The Trend in the Analyst Price Target
Over the past 156 days, TNXP's average price target has gone down $0.13.
TNXP Broker Recommendations Summary
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
What other stocks do shareholders of Tonix Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).
When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?
Tonix Pharmaceuticals's stock reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
What is Tonix Pharmaceuticals' official website?
The official website for Tonix Pharmaceuticals is www.tonixpharma.com.
How many shares of Tonix Pharmaceuticals are there after the split?
The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
What is the official website of Tonix Pharmaceuticals?
The official website for Tonix Pharmaceuticals is www.tonixpharma.com.
What is the P/E ratio of Tonix Pharmaceuticals?
The P/E ratio of Tonix Pharmaceuticals is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Stock Price Forecast
The 1 analysts offering 12-month price forecasts for Tonix Pharmaceuticals Holding Corp have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +1,438.46% increase from the last price of 0.20.
Analyst Recommendations
The current consensus among 1 polled investment analysts is to Buy stock in Tonix Pharmaceuticals Holding Corp. This rating has held steady since November, when it was unchanged from a Buy rating. Move your mouse over past months for detail
TNXP Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
How many people will be affected by TNX-1900?
Approximately Four Million in U.S. Suffer from Chronic Migraine Development of TNX-1900 Also Planned for Treatment of Episodic Migraine, Craniofacial Pain and Insulin Resistance CHATHAM, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to support the initiation of a Phas
What is the TNX 102 SL?
Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Condition Afflicts More Than 30 Percent of Patients Post Infection with SARS-CoV-2, the Virus that Causes COVID-19 Pre-IND Meeting with FDA Scheduled for Q3 2021 CHATHAM, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today anno
When will Tonix be added to the Russell 3000?
CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the annual reconstitution of the Russell stock indexes. "Tonix is pleased to be included in the Russell indexes which reflects our positive achie
When was Tonix patent issued?
CHATHAM, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,167,010 on November 9, 2021. The patent, entitled “Trefoil Family Factor Proteins and Uses Thereof,” includes claims directed to an isolated polypeptide comprising a carboxy-terminal (CTP) domain of the beta subunit of the human chorionic gonadotro
Is TNX-3500 a potent antiviral?
Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates RemdesivirCHATHAM, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight. The paper includes in vitro s
Is Tonix Pharmaceuticals a biotech?
Tonix Pharmaceuticals (NASDAQ: TNXP), a rather up-and-down meme stock in the biotech sector, was having a fine day on the market Tuesday. Tuesday morning, Tonix was all too happy to announce that the Food and Drug Administration (FDA) has cleared the Investigational New Drug application for its TNX-1900. The treatment of migraines has been a thorny challenge for biotechs and pharmaceutical companies for many years.
How is Tonix target price determined?
Tonix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tonix target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Where do analysts publish their price targets?
Note that most analysts generally publish their price targets in research reports on specific companies , along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Tonix Pharm Holdings and the information provided on this page.
How often does Tonix issue ratings?
Most Tonix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tonix stock's fair price compared to its market value.
What is the data published in Tonix Pharm's financial statements?
The data published in Tonix Pharm's official financial statements usually reflect Tonix Pharm's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Tonix Pharm Holdings. For example, before you start analyzing numbers published by Tonix accountants, it's critical to develop an understanding of what Tonix Pharm's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
How often do Tonix analysts give ratings?
Most Tonix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tonix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tonix Pharm Holdings, talking to its executives and customers, or listening to those companies' conference calls.
Why is the target price unavailable?
If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now.
Is Tonix Pharm a financial analysis?
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Tonix Pharm. Your research has to be compared to or analyzed against Tonix Pharm's peers to derive any actionable benefits. When done correctly, Tonix Pharm's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Tonix Pharm Holdings.
